Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges

This publication has 36 references indexed in Scilit:

• The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
  The Lancet Infectious Diseases, 2015
• Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice
  Vaccine, 2013
• Purification and Characterization of Enterovirus 71 Viral Particles Produced from Vero Cells Grown in a Serum-Free Microcarrier Bioreactor System
  PLOS ONE, 2011
• Clinical features, diagnosis, and management of enterovirus 71
  The Lancet Neurology, 2010
• Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences
  Infection, Genetics and Evolution, 2010
• Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
  Vaccine, 2008
• Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge
  Vaccine, 2008
• Vesicular stomatitis virus: re-inventing the bullet
  Trends in Molecular Medicine, 2004
• An overview of the evolution of enterovirus 71 and its clinical and public health significance
  FEMS Microbiology Reviews, 2002
• Neurologic Complications in Children with Enterovirus 71 Infection
  New England Journal of Medicine, 1999